We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Abionyx Pharma | EU:ABNX | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.112 | 8.93% | 1.366 | 1.30 | 1.376 | 1.482 | 1.28 | 1.29 | 526,229 | 16:40:00 |
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announces that it has filed with the “Autorité des Marchés Financiers” (AMF) its Universal Registration Document for the year ended December 31, 2022, dated April 28, 2023.
ABIONYX Pharma's Universal Registration Document for the financial year ending December 31, 2022, includes in particular:
This document is available on the company's website (www.abionyx.com) and on the AMF website (www.amf-France.org). It is also available at the company's registered office, 33-43 avenue Georges Pompidou - Building D, Balma, 31130.
The Universal Registration Document has also been published in European Single Electronic Format (ESEF), with the five tables of the consolidated financial statements (the primary financial statements) and the appendix marked up using the XBRL markup language.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005884/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu +33 (0)1 44 71 94 98
1 Year Abionyx Pharma Chart |
1 Month Abionyx Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions